{"nct_id":"NCT04924062","title":"Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study","status":"COMPLETED","status_verified_date":"2025-04","start_date":"2020-07-10","start_date_type":"ACTUAL","primary_completion_date":"2022-12-15","primary_completion_date_type":"ACTUAL","completion_date":"2025-03-25","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["MRK"]}